Monitor the ICCBH 2026 presentation on June 28 for any unexpected efficacy or safety signals that could move the stock. The PROPEL 3 data has already been disclosed — this is a conference re-presentation, not a new catalyst. No trade action warranted based on this press release alone.
Price Chart
Executive Summary
BridgeBio announced additional positive data from the Phase 3 PROPEL 3 study of oral infigratinib in achondroplasia will be presented at ICCBH 2026, alongside other skeletal dysplasia and ADH1 data. This is a routine pipeline update with no new regulatory or commercial catalyst — the data was previously disclosed and the presentation is a conference update, not a new approval or trial result.
Key Facts
- Positive data from PROPEL 3 Phase 3 study of oral infigratinib in achondroplasia to be presented in late-breaking oral at ICCBH 2026 on June 28.
- Additional presentations include quality-of-life findings from PROPEL observational study, Phase 2/2b design for children under 3, and ADH1 CLARIFY study poster.
- No new regulatory filing, approval, or commercial milestone announced — this is a conference data presentation update.
Financial Impact
No financial figures disclosed; pipeline update with no immediate revenue or cost impact.
Risk Factors
- Conference presentations rarely move stock unless they contain material new data not previously disclosed — this appears to be a re-presentation of known PROPEL 3 results.
- No timeline for regulatory submission or approval of infigratinib in achondroplasia was provided.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3315189 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access